Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent of renal damage. In pediatric SLE, and particularly in lupus nephritis, activation of the IFN-I pathway has never been studied, nor is it known whether monogenic forms underlie more pronounced interferon activation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Difference between monogenic and non-monogenic forms of cSLE
Timeframe: At the enrollment, in case of renal flare, in case of disease remission
Evaluation of expression of MXA protein in renal biopsy
Timeframe: Biopsy available at enrollment
Evaluation of the proportions of the various WHO histological classes of renal biopsy
Timeframe: At the end of the study (24 months after enrollment)